Portolan Capital Management’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
Portolan Capital Management's CSTL Position: Q3 2026 in Review
Portolan Capital Management increased its Castle Biosciences (CSTL) stake by 318% in Q3 2026, buying an estimated $31.5M and bringing the position to 1,372,870 shares worth $48.8M. The position accounts for 1.99% of the portfolio, ranked #8.
Portolan Capital Management first reported a position in CSTL in Q3 2019 and has held it in 25 quarters since. The position peaked at $67.3M in Q4 2025. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- Portolan Capital Management held 1,372,870 shares of Castle Biosciences worth $48.8M as of Q3 2026.
- Portolan Capital Management bought 1,044,052 Castle Biosciences shares in Q3 2026, an estimated $31.5M.
- Castle Biosciences made up 1.99% of Portolan Capital Management's portfolio in Q3 2026, its #8 holding.
- Portolan Capital Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 25 quarters since.
- Portolan Capital Management's Castle Biosciences position peaked at $67.3M in Q4 2025.
- 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on Portolan Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.